A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study

Helicobacter

Volumn 20, Issue 5, 2015, Pages 390-396

  Ciccaglione, Antonio Francesco ^a   Cellini, Luigina ^a   Grossi, Laurino ^a   Manzoli, Lamberto ^a   Marzio, Leonardo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

DOX; Amoxicillin; Bismuth subcitrate; First line therapy; Helicobacter pylori infection; Quadruple therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; DOXYCYCLINE; ESOMEPRAZOLE; ANTIINFECTIVE AGENT; BISMUTH; PROTON PUMP INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BREATH ANALYSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UREA BREATH TEST; COMBINATION DRUG THERAPY; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; DOXYCYCLINE; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941738868     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12209     Document Type: Article

References (50)

1. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.
2. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high grade transformed MALT lymphoma. J Natl Cancer Inst 2005;97:1345-53.
3. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Mégraud F, Xiao SD, Sugano K, Nyrén O; Lejondal H. pylori-Gastric Cancer Task Force. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100-15.
4. Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol 2010;5:639-48.
5. Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The optimal first-line therapy of Helicobacter pylori infection in year 2012. Gastroenterol Res Pract 2012;2012:168361.
6. Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol 2009;104:26-30.
7. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7:306-9.
8. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
9. Megraud F. H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut 2004;53:1374-84.
10. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010;8:59-70.
11. Falush D, Kraft C, Taylor NS, et al. Recombination and mutation during long-term gastric colonization by Helicobacter pylori: estimates of clock rates, recombination size, and minimal age. Proc Natl Acad Sci USA 2001;98:15056-61.
12. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;2:280-322.
13. Quasim A, O'Marian CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16:24-30.
14. Broutet N, Tchamgoue S, Pereira E, Lamouliattel H, Salomon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17:99-109.
15. Fischbach LA, Van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
16. Calvet X, Lopez-Lorente M, Cubells M, Bare M, Galvez E, Molina E. Two-week dual vs. one-week triple therapy for cure for Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment Pharmacol Ther 1999;13:781-6.
17. Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther 2003;18:543-4.
18. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, AMO, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter. North American trial. Am J Gastroenterol 2003;98:562-7.
19. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth citrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011;377: 905-13.
20. Huang JQ, Hunt RH. Treatment after failure. The problem of 'non-responders'. Gut 1999;45:140-4.
21. Farup PG, Tholfsen J, Wetternus S, Torp R, Hoie O, Lange OF. Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scand J Gastroenterol 2002;37:1374-9.
22. Tursi A, Brandimarte G, Giorgetti G, Modeo ME, Gigliobianco A. Efficacy and tolerability of ranitidine bismuth citrate plus amoxicillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection. Hepatogastroenterology 2002;49:1006-9.
23. Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regime versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of DOX, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci 2009;54:599-603.
24. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
25. Ikenberry SO, Harrison ME, Lichtenstein D, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc 2007;66:1071-5.
26. Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train 2008;43:215-21.
27. Healy DP, Dansereau RJ, Dunn AB, Clendening CE, Mounts AW, Deepe GS Jr. Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. Ann Pharmacother 1997;31:1460-4.
28. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
29. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G; Working Group of the Cervia II Meeting. Cervia II Working Group Report 2006: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-9.
30. Malfertheiner P, Megraud F, O'Marian C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
31. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60.
32. Ribeiro ML, Gerrits MM, Benvengo YHB, et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol 2004;40:57-61.
33. Smilack JD. Symposium on antimicrobial agents - part X: the tetracyclines. Mayo Clin Proc 1999;74:727-9.
34. Perri F, Festa V, Merla A, Quitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter 2002;7:99-104.
35. Akyildiz M, Akay S, Musoglu A, Tuncyurek M, Aydin A. The efficacy of ranitidine bismuth citrate, amoxicillin and DOX or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med 2009;20:53-7.
36. Almeida N, Romaozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and DOX is useless for Helicobacter pylori eradication: a proof-of-concept study. Helicobacter 2014;19:90-7.
37. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and DOX versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-5.
38. Sanches B, Coelho L, Moretzsohn L, Vieira G Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter 2008;13:572-6.
39. Usta Y, Saltik-Temizel IN, Demir H, Uslu N, Ozen H, Gurakan F, Yuce A. Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection. J Gastroenterol 2008;43:429-33.
40. Wang Z, Wu S. DOX-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012;53:273-6.
41. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week DOX- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004;19:789-95.
42. Rodgers C, van Zanten SV. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol 2007;21:295-300.
43. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988;36:132-57.
44. Malfertheiner Peter. Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol 2010;7:538-9.
45. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y; Study Group Participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
46. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;14:5385-402.
47. Andersen LP. Colonization and infection by Helicobacter pylori in humans. Helicobacter 2007;12:12-5.
48. Cole SP, Harwood J, Lee R, She R, Guiney DG. Characterization of monospecies biofilm formation by Helicobacter pylori. J Bacteriol 2004;186:3124-32.
49. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-22.
50. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010;35:322-32.